Coronavirus vaccine race will boost Moderna, Inc.(MRNA) even higher
Moderna, Inc. currently trades at $27.75 and has seen losses of 7% in the past month. Moderna, Inc. has seen a decrease in revenue in the past four quarters. Recently, MRNA used mRNA, a genetic form of the virus’ genome, and the vaccine targets the Spike (S) protein of the coronavirus. The company has entered into a phase-one human clinical trial. The trial began on Mar 16 at the Kaiser Permanente Washington Health Research Institute in Seattle, with 45 males and females aged between 18 and 45 enrolled for the same so far. This makes Moderna, Inc. this makes MRNA great buy because MRNA has short term potential to capitalize on the coronavirus vaccine race. The Zacks Consensus Estimate for the company’s current-year earnings has been revised 6.2% upward over the past 60 days. Moderna carries a Zacks Rank #2. Moderna’s dividends sit at 0% and has a market cap of $8.93 billion. In the past 5 years, the stock has grown 45%, making the company something you want on your portfolio. Overall, Moderna, Inc. is a stock you want to keep an eye out for, yesterday the stock closed at $27.13 leaving investors up 9.81% in the past 24 hours. Moderna, Inc.’s high 1-year forecast is 40 with a low of 30.